OTC drugs get boost in FDA budget request
This article was originally published in The Tan Sheet
Executive Summary
The Obama administration's $457.8 million fiscal year 2010 budget request for FDA's human drugs activities includes $15.1 million for over-the-counter products, which would represent a 1.1 percent increase over the fiscal 2009 appropriation of $14.9 million, according to the Department of Health and Human Services justification of estimates for appropriations committees document. Among FDA's planned activities for fiscal 2010, it intends to make "significant progress" on five OTC drug monographs and act on 100 percent of all Rx-to-OTC switch applications within 10 months of receipt, the agency says in its performance appendix. An FDA spokesman was unable to break the OTC drug request number down into more specific activities
You may also be interested in...
FDA Budget In Brief
Drug program proposal: FDA requests $1 billion in fiscal 2011 funding for its human drug program, a 13.6 percent increase from the prior-year appropriation, more than half of which would be covered by user fees. The figure presented Feb. 1 in the Obama administration's proposed budget includes $849.7 million for activities within the Center for Drug Evaluation and Research, and $150.5 million for Office of Regulatory Affairs field operations. The agency seeks $446.5 million for new drug review functions across both CDER and ORA. One area of ORA's domestic program - the OTC monograph project and health fraud project inspections - seeks $95 million for fiscal 2011, which would match the 2010 estimate. Of the $1 billion total for drug activities, $516 million is projected to come from user fees - largely those existing under the Prescription Drug User Fee Act. However, $34.4 million in new generic drug user fees and $2.5 million in field re-inspection user fees are proposed for fiscal 2011. The user fee component would represent 51.6 percent of total drug program funding in fiscal 2011, up from 47.2 percent of the 2010 appropriation
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.